Close
Almac
Achema middle east

Recipharm bolsters senior leadership team with appointment of Joaquim Mascaro as Chief Financial Officer

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.
- Advertisement -

Global contract development and manufacturing organisation (CDMO) Recipharm, has announced the appointment of Joaquim Mascaro as Chief Financial Officer.

Joaquim has worked for a range of organisations in the pharma, biotech and healthcare industries, across the US, Asia and Latin America. His experience in building and developing strong teams will be essential in supporting the organisation through its next phase of growth.

Marc Funk, CEO Recipharm said: “I am delighted to welcome Joaquim to the Recipharm team as we continue to drive our business forward. Joaquim’s impressive credentials and expertise will be a real asset to the senior leadership team and to the business”.

Commenting on his appointment, Joaquim said: “Recipharm’s reputation and service offering in the industry is second to none. I am thrilled to be working for a leading top five CDMO on the quest for continuous growth”.

Joaquim joins on 3 April 2023 and replaces Michael Tyroller, who was interim CFO.

Latest stories

Related stories

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »